Genentech says drug combo reduces breast cancer recurrence

09/14/2005 | Forbes

Interim data from the company's Phase III trials indicates its Herceptin cancer drug used in combination with standard chemotherapy drugs reduced the risk of the disease returning by 39% to 51%, compared with chemotherapy by itself. The study involved 3,000 women with early-stage HER2-positive breast cancer, a type of cancer that accounts for about one in four breast cancers.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX